Solid Biosciences (NASDAQ:SLDB) was upgraded by equities researchers at Svb Leerink from a “market perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The firm presently has a $15.00 price objective on the stock, up from their previous price objective of $8.00. Svb Leerink’s target price suggests a potential upside of 60.94% from the company’s current price. Svb Leerink also issued estimates for Solid Biosciences’ Q3 2019 earnings at ($0.58) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($2.68) EPS, Q1 2020 earnings at ($0.52) EPS, Q2 2020 earnings at ($0.49) EPS, Q3 2020 earnings at ($0.46) EPS, Q4 2020 earnings at ($0.40) EPS, FY2020 earnings at ($1.85) EPS, FY2021 earnings at ($1.50) EPS, FY2022 earnings at ($1.46) EPS and FY2023 earnings at ($0.81) EPS.

Several other research firms also recently weighed in on SLDB. Zacks Investment Research upgraded shares of Solid Biosciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Leerink Swann upgraded shares of Solid Biosciences from a “market perform” rating to an “outperform” rating in a research report on Monday. Chardan Capital upgraded shares of Solid Biosciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $7.50 to $10.00 in a research report on Friday, August 16th. Citigroup set a $6.00 price target on shares of Solid Biosciences and gave the stock a “hold” rating in a research report on Thursday, May 16th. Finally, ValuEngine upgraded shares of Solid Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $8.21.

SLDB opened at $9.32 on Monday. Solid Biosciences has a twelve month low of $4.32 and a twelve month high of $54.54. The company has a quick ratio of 5.73, a current ratio of 5.73 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $5.80 and a 200 day moving average price of $7.96. The company has a market cap of $311.92 million, a PE ratio of -4.14 and a beta of 2.07.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.05. As a group, sell-side analysts expect that Solid Biosciences will post -3.05 earnings per share for the current year.

In other Solid Biosciences news, Director Life Sciences Maste Perceptive acquired 2,822,581 shares of the business’s stock in a transaction on Thursday, July 25th. The stock was bought at an average price of $4.65 per share, for a total transaction of $13,125,001.65. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 31.20% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in SLDB. Walleye Trading Advisors LLC acquired a new stake in Solid Biosciences during the 2nd quarter worth $210,000. Walleye Trading LLC acquired a new stake in Solid Biosciences during the 2nd quarter worth $214,000. Cubist Systematic Strategies LLC acquired a new stake in Solid Biosciences during the 2nd quarter worth $70,000. AQR Capital Management LLC acquired a new stake in Solid Biosciences during the 2nd quarter worth $255,000. Finally, EcoR1 Capital LLC acquired a new stake in Solid Biosciences during the 2nd quarter worth $4,755,000. Institutional investors own 60.06% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

See Also: What is the definition of a trade war?

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.